. Heatmap demonstrating the specific sequence of drugs used for each patient in in the cohort of 194 mRCC patients. The 9 most commonly used drugs are shown individually, and the rest are included in the category of "Other", which includes investigational agents, cabozantinib, interleukin-2, ipilimumab, lenvatinib. Figure S2 . Three-month clinical benefit correlates with best clinical response during treatment, Chi squared analysis. Best clinical response assessments were recorded for 400 lines of therapy and were divided into two groups: those with complete response, partial response, or stable disease (called response) and those with progressive disease (called no response). Chi square analysis to determine the association between our "clinical benefit" (yes vs. no) and best clinical response measurements (response vs no response). 
